INCY
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCHIncyte Corporation - Common Stock (INCY) [ST]
www.incyte.com ↗▲ 0.30%
prev close
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-05-15 | INCYIncyte Corporation - Common Stock | Sell | $1,001 - $15,000 | 306d ago | — |
2025-05-15
Rob Bresnahan
INCY
Amount
$1,001 - $15,000
Filed
306d ago
Recent News
Powered by Polygon.io
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market
Trade Timeline
Congressional activity, newest first
Rob Bresnahan
2025-05-15 · Sale
$1,001 - $15,000